RT-PCR methods have been developed, to date, by various groups to amplify the PML-RARA fusion gene produced by the t(15;17) in APL patients. However, these methods lack the necessary sensitivity to detect minimal residual disease (MRD) below the level of 1 leukaemic cell in 10 4 cells. Patients who test positive by these methods after treatment are likely to relapse. However, up to 25% of patients who test negative after treatment relapse within a short period. We have developed a 'hotstart' RT-PCR method for the amplification of PML-RARA with increased sensitivity at the level of two leukaemic cells in 10 6 cells. Using this method we were able to detect MRD in seven out of 15 patients tested in remission. Of the 11 patients in medium to long-term remission, five patients tested positive.
Introduction
Acute promyelocytic leukemia (APL) is characterised by the presence of the t(15;17), which was first described in 1977. 1 This translocation fuses the PML gene on 15q and RARA gene on 17q to produce two transcriptionally active fusion genes PML-RARA and RARA-PML. [2] [3] [4] [5] [6] Transcripts for PML-RARA were detected in all patients with t(15;17) while RARA-PML transcripts were detected in approximately 70% of cases. 4 RT-PCR methods developed for the amplification of PML-RARA transcripts have been used for diagnosis and in monitoring minimal residual disease (MRD). 4, [6] [7] [8] [9] [10] [11] [12] [13] However, although serial negative tests for PML-RARA are generally associated with prolonged remission, up to 25% of those patients could relapse within a short period after testing negative. 7, 9, 12, 13 This is due to the fact that current RT-PCR methods have a sensitivity not higher than 10 −4 , which is 2 logs lower than corresponding methods for other fusion genes. These methods lack the necessary sensitivity to detect the presence of very low levels of leukemic cells present during stable remission. For this reason, some researchers have 'incorrectly' stated, that in patients in long-term remission who test negative for PML-RARA, the disease has been eradicated. 14 We have developed a more sensitive 'hot-start' RT-PCR method for the amplification of PML-RARA and have used it to monitor minimal residual disease in patients with APL.
Materials and methods

Patients
Bone marrow (BM) samples were collected from 15 patients in complete remission (CR) of APL for between 3 and 82 Correspondence: K Tobal; Fax: 161 2764088 months. Three of the patients were also tested at presentation. Mononuclear cells (MNCs) were separated from BM samples and either used immediately or stored at −70°C. Between 1 × 10 6 and 2 × 10 6 cells were used for RNA isolation. All patients were diagnosed as having APL (AML-M3) according to FAB classification 15 and t(15;17) by karyotypic analysis. They all received standard intensive remission induction chemotherapy with an anthracycline/anthracenedione, cytosine arabinoside ± thioguanine and two courses of consolidation chemotherapy with the same agents, followed by autologous or allogeneic bone marrow transplant (BMT) in some patients. Patients who did not receive BMT received a fourth course of intensive chemotherapy with mitozantrone and an intermediate dose of cytosine arabinoside. Only three patients (Nos 8, 10, 11) received short courses of all-trans retinoic acid (ATRA) (5-7 days) prior to induction chemotherapy to correct existing coagulopathies. No patient received maintenance with ATRA. Pre-BMT conditioning comprised daunorubicin (60 mg/m 2 ), cyclophosphamide (120 mg/m 2 ) and TBI (1000 cGy) in two fractions for allograft or melphalan (120 mg/m 2 ) and TBI for autograft. The remission BM karyotypes were normal in all patients.
RNA extraction
RNA was extracted from samples by a minor modification of the Chomczynski and Sacchi method. 16 Four hundred microlitres of guanidinium solution were added to 250 l of MNC samples and vortexed. Sixty-five microlitres of 2 M sodium acetate pH 4.0 were added and vortexed again. Mixes were incubated at room temperature for 10 min before 650 l of water saturated phenol were added and the mixture was homogenised with a 17G syringe needle to release RNA and sheer DNA. Then, 130 l of chloroform were added and the mixture vortexed again and incubated on ice for 15 min. The mixtures were centrifuged at 14 000 g for 20 min and the upper aqueous layer was transferred to a new tube and mixed with an equal volume of isopropanol and stored at −70°C overnight. RNA was precipitated by centrifugation at 14 000 g for 15 min and washed with 70% ethanol. After drying, RNA pellets were suspended in sterile water and quantified by spectrophotometry.
RT reaction
Ten microlitres (7 g) of RNA were heated at 72°C for 5 min and snap-cooled on ice. RT reaction mixture (final concentration in a 20 l reaction volume: 1 × first strand buffer, 10 mM DTT, 0.25 g pd(N)6, 1 mM dNTPs, 200 U MMLV, 40 U RNAsin) was then added to the RNA and incubated at room temperature for 10 min. RT reaction was carried out at 37°C for 1 h, 45°C for 30 min and 72°C for 5 min.
Standard 'cold-start' PCR
Five microlitres of cDNA were added to a final volume of 50 l of first-round PCR reaction buffer containing as final concentrations: 1 × PCR buffer (Gibco-BRL), 0.2% W-1 (detergent; Gibco-BRL), 1.5 mM MgCl 2 , 0.25 mM dNTPs, 15 pmol of primers M4 and RAR (Figure 1 ), 2 U Taq DNA polymerase. PCR amplification was carried out for one cycle at 94°C, 2 min, followed by 40 cycles at 93°C for 1 min, 55°C for 1 min, 72°C for 1 min, and finally one cycle at 72°C for 5 min. Then, 5 l of first-round reaction was added to a final volume of 50 l of second-round reaction buffer containing 15 mol of primers 2 and R8. PCR amplification was carried out as for the first round.
Second-round products were electrophoresed on a 2% agarose gel.
New 'hot-start' touchdown PCR
Forty microlitres of first-round PCR mix was prepared by mixing 5 l 10 × PCR buffer (Gibco-BRL), 2.5 l W-1, 1.5 l 50 mM MgCl 2 , 0.5 l 25 mM dNTPs, 1 l 15 M primers M4
Figure 1
Diagrammatic description of the different fusion points for PML-RARA and primers used for their amplification.
and RAR (for BCR3 'S-form' PML-RARA) or M1 and RAR (for BCR 1 and BCR2 'L and V-forms' PML-RARA) ( Figure 1 ), and 2 U Taq DNA polymerase. The PCR mix was heated for 2 min at 94°C then cooled at 80°C while 10 l of cDNA was added to each tube. Touchdown PCR reaction was then carried out as follows: one cycle at 94°C for 2 min, two cycles of 93°C for 1 min, 60°C for 1 min, 72°C for 1 min. This was followed by a reduction of the annealing temperature by 1°C every second cycle until it reached 55°C. This was then followed by 40 cycles with annealing at 55°C and finally 1 cycle of 72°C for 5 min. Then, 7 l of first-round reaction was added to a 43 l second-round PCR reaction buffer containing 15 mol of primers 2 and R8 (for S-form PML-RARA) or primers M2 and R8 (for L and V-form PML-RARA) after heating to 94°C for 2 min and cooling to 80°C. PCR amplification was then performed as for the first round. Second-round products were electrophoresed on a 2% agarose gel.
Control tests
Normal PML gene was amplified as a control gene to assess the viability of RNA isolated from samples. All tests were car-ried out with normal samples as negative controls and NB4 cell line as a positive control.
Sensitivity analysis
Serial dilutions were made with normal MNCs from the NB4 cell line, 17 which has an L-form PML-RARA fusion gene, or a presentation sample from an APL patient with an S-form PML-RARA. These dilutions were used in comparing sensitivity of different methods for the amplification of PML-RARA.
Results
Sensitivity analysis
Sensitivity of the standard 'cold-start' RT-PCR was found to be in one leukaemic cell in 10 4 normal cells (10
) for the L-form PML-RARA and two leukaemic cells in 10 5 normal cells for the S-form PML-RARA. Introducing individual changes resulted in some instances of a small but significant increase in sensitivity. Introducing a single change to the procedure, such as the use of primer M2 instead of primer 2 for the L and V-form PML-RARA or increasing the amount of cDNa used or the number of cycles used for both rounds of PCR alone did not alter the sensitivity of amplification. On the other hand, the introduction of 'hot-start' PCR with increased amounts of cDNA and number of PCR cycles, but with sense primers M4 and 2, increased the sensitivity of the method by 1 log. Alteration to the protocol by changing the position of primers used including the use of specfic primers for both rounds of PCR for the amplification of S-form 'M4 and 2' and L and V-form 'M1 and M2' in a 'hot-start' PCR increased the sensitivity of detection to 2 leukaemic cells in 10 6 normal cells (2 × 10 −6 ) for both types of fusion transcripts.
Using the sense primers M4 and 2 on the NB4 cell line, RNA produced a number of expected bands, 722 bp, 578 bp, 319 bp, which correspond to those detected by other groups. 4 Band 319 bp appeared in low dilution only. This could be explained by a higher efficiency of amplification for this spliced transcript at low dilution. The amplification of this spliced transcript from samples with L or V-forms has been reported previously. 4 An example of the comparison between a standard 'coldstart' method and the new 'hot-start' method, which include all the alterations documented above, is shown in Figure 2 .
Patient analysis
All presentation samples were positive for PML-RARA when tested by both standard 'cold-start' and new 'hot-start' methods. All remission samples from the 15 patients were negative for PML-RARA using the standard methods (coldstart). However, using the new 'hot-start' RT-PCR method described here, seven patients (one of two allo BMT, two of five auto BMT, and four of eight chemotherapy) were positive for PML-RARA (Figures 3 and 4) . These patients were in continuous remission from 3 to 82 months, and of these, five were in continuous medium to long-term remission ranging from 32 to 82 months (Figure 4) , and all remain in remission. Two of the seven patients have S-form, one patient has V-form, and four patients have L-form.
Discussion
APL is highly responsive to the differentiating agent all-trans retinoic acid and also to chemotherapy. Although APL has a favourable clinical outcome, relapse remains a common problem. Methods developed to date by different groups for the amplification of PML-RARA transcripts have a low sensitivity level which is around one leukemic cell in 10 4 normal cells (10 −4 ). This could explain the failure of these methods to detect MRD in patients in remission of APL. This failure was most noticeable in patients who relapsed within short periods after testing negative for PML-RARA. Using these standard protocols, a persistent positive test for PML-RARA after treatment correlates highly with subsequent relapse. 7 However, up to 25% of patients tested negative with these protocols did convert to positive and relapsed shortly afterwards, 7, 9, 12, 13 although a recent report by Lo Coco et al 18 suggests that the rate of relapse is small in patients, post-induction, who remain persistently RT-PCR negative. It thus became clear that a more sensitive RT-PCR method to detect PML-RARA transcripts for monitoring MRD was required.
We have described here a number of improvements that could be made to increase the sensitivity of PML-RARA transcript amplification by RT-PCR. These changes included the use of larger amounts of cDNA and first-round PCR products in the first-and second-round PCR, respectively. They also included increasing cycle numbers for first-and second-round PCR, the use of hot-start PCR, designing specific primers for the different breakpoint fusion gene, and touchdown PCR. The design of separate PCR methods for the amplification of the different types of PML-RARA transcripts (S-form and L or Vforms) produced by different positions of breakpoints in the PML gene (Figure 1 ) avoids the amplification of the PML sequences that lie between the two areas. It is generally agreed that the amplification of the S-form PML-RARA has a better sensitivity than the amplification of the L or V-form PML-RARA by the standard methods, and this was shown by the sensitivity analysis performed in this study. This suggests that avoiding the amplification of this area may help to increase the sensitivity of L or V-form PML-RARA amplification. We assessed the role played by the inclusion of PML sequences which lie between the BCR3 and BCR2 breakpoint areas on PML (Figure 1 ) in the sensitivity of PML-RARA amplification by amplification of PML using either sense primer M4 or M1 (results not shown). This comparative amplification showed a large increase in the level of amplification of PML using the sense primer M1 (avoiding the amplification of the above sequences). This was shown by the production of a single intense band with primer M1 and very faint multiple bands with primer M4.
Introducing these changes individually produces either no change or a small change in senstivity. An example of changes which produced small but significant increases in sensitivity was the use of 'hot-start' PCR with an increased number of cycles, which increased the method sensitivity by 1 log. However, including all these changes together, produced an increase in sensitivity of approximately 2 log. We have found that the use of touchdown PCR improved the consistency and reproducibility of results.
We have shown in this study that all patients in remission of APL following chemotherapy are negative for PML-RARA using standard methods, which is consistent with published work.
7,9 However, we were able to detect PML-RARA transcripts in seven of 15 patients in remission using the more sensitive method described here. This method was able to detect PML-RARA transcripts in patients with all different forms of PML-RARA transcripts where standard methods failed. Five of these patients are in continuing remission between 32 and 82 months, and have received various treatments including chemotherapy alone, autologous and allogeneic BMT. All these patients remain in stable remission. These results are in keeping with our previous work which showed that some APL patients in long-term remission are positive for the reciprocal fusion gene RARA-PML transcripts. 6 Although a number of groups have worked on improving the sensitivity of PML-RARA amplification, 19, 20 this study is the first to show that improving method sensitivity could detect the persistence of PML-RARA transcripts in patients in longterm remission.
Due to the lack of sensitivity of the methods used by other groups, it has been suggested by some researchers that APL patients in long-term remission, who consistently test negative for PML-RARA, are cured of their disease with eradication of residual leukemia.
14 However, our results clearly show the persistence of leukemic cells with t(15;17) in patients in longterm remission, who can be considered clinically 'cured' of their disease. Similarly, residual leukemic cells have been detected by sensitive RT-PCR methods in long-term survivors from AML with t(8;21). 21, 22 In our series, six patients in remission for 36-70 months, tested negative for PML-RARA with the new method. This suggests that these patients may either have disease below the level detectable by the current method or perhaps even have their disease truly eradicated. The significance of the residual leukemic cells with t(15;17) remains unknown, but our findings provide new insights into the biology of APL. This implies that an additional event or 'hit' may be necessary in patients with t(15;17) before the onset of overt leukemia and is in keeping with the hypothesis of multi-step pathogenesis of leukemia.
It is likely that this new RT-PCR method is far too sensitive for it to be clinically useful in a qualitative approach for monitoring MRD in APL. However, to be able to monitor MRD successfully in all APL patients such a sensitive method is required in quantitative RT-PCR technique. We believe that this method, used in a quantitative RT-PCR similar to that used for AML1-MTG8 transcripts in AML with t(8;21), 23 may offer a valuable additional technique for monitoring MRD in APL. Only a quantitative RT-PCR method with a comparable sensitivity to the method described here could enable the determination of the threshold of residual PML-RARA transcripts compatible with long-term remission in APL. Such a technique could be useful in distinguishing all patients at low risk from those at high risk of relapse, thus allowing specific treatment to be tailored to individual patients. Clearly, there is a need to study a large number of APL patients undergoing different modalities of treatment (eg ATRA, chemotherapy, BMT) to determine the influence of therapy on the level of MRD in remission patients.
